Sodium-glucose cotransporter 2 inhibitors (SGLT2i), including empagliflozin, dapagliflozin, and canagliflozin, have emerged as a promising class of medications with some antihypertensive effects, in addition to their established benefits in type 2 diabetes mellitus (T2DM) and HF (58–60). Here, SLC5A2 is linked to diabetes mellitus.